We are live on
!
Find out more
Marshall Wace North America Portfolio holdings
AUM
$23.5B
Turnover
51.87%
1-Year Est. Return
46.46%
This Fund
S&P 500
This Quarter
Est. Return
+8.89%
1 Year Est. Return
+46.46%
3 Year Est. Return
+108.51%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$14.6B
AUM Growth
-$3.14B
(-18%)
Cap. Flow
-$4.07B
Cap. Flow
% of AUM
-27.91%
Top 10 Holdings %
Top 10 Hldgs %
20.74%
Holding
1,655
New
313
Increased
216
Reduced
349
Closed
770
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
0.5
years
Top 20 Avg Time Held Equity + Options
0.6
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$214M |
| 2 |
Medtronic
MDT
|
+$123M |
| 3 |
Charter Communications
CHTR
|
+$97.9M |
| 4 |
Merck
MRK
|
+$94M |
| 5 |
Zoetis
ZTS
|
+$91.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$253M |
| 2 |
Baidu
BIDU
|
+$120M |
| 3 |
Constellation Brands
STZ
|
+$110M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$104M |
| 5 |
Abbott
ABT
|
+$98.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.88% |
| 2 | Technology | 16.43% |
| 3 | Industrials | 11.26% |
| 4 | Consumer Discretionary | 9.94% |
| 5 | Financials | 9.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Microsoft
MSFT
$3.91T
| $487M | 3.34% |
4,254,065
-821,310
| -16% | -$89M |
2017 Q1
6 quarters
|
|
|
2
Zoetis
ZTS
$32.6B
| $385M | 2.64% |
4,202,241
+1,034,161
| +33% | +$91.7M |
2013 Q2
21 quarters
|
|
|
ABMD
3
DELISTED
Abiomed Inc
ABMD
| $310M | 2.13% |
690,160
+214,655
| +45% | +$84.6M |
2017 Q1
6 quarters
|
|
4
Boston Scientific
BSX
$63.9B
| $282M | 1.94% |
7,333,396
-1,615,233
| -18% | -$56.4M |
2017 Q1
6 quarters
|
|
5
Global Payments
GPN
$22B
| $275M | 1.89% |
2,162,102
+655,495
| +44% | +$78.8M |
2017 Q2
5 quarters
|
|
6
UnitedHealth
UNH
$361B
| $272M | 1.87% |
1,022,572
+39,318
| +4% | +$10.2M |
2017 Q1
6 quarters
|
|
7
S&P Global
SPGI
$126B
| $271M | 1.86% |
1,387,773
+81,878
| +6% | +$16.9M |
2017 Q1
6 quarters
|
|
|
8
Alphabet (Google) Class A
GOOGL
$4.16T
| $270M | 1.85% |
4,468,700
+3,537,400
| +380% | +$214M |
2017 Q1
6 quarters
|
|
9
Pfizer
PFE
$168B
| $236M | 1.62% |
5,655,623
+1,105,422
| +24% | +$42.6M |
2013 Q2
21 quarters
|
|
10
CoStar Group
CSGP
$12.9B
| $231M | 1.58% |
5,481,940
+773,730
| +16% | +$33.1M |
2017 Q1
6 quarters
|
|
|
11
Merck
MRK
$362B
| $228M | 1.57% |
3,368,259
+1,475,797
| +78% | +$94M |
2017 Q1
6 quarters
|
|
12
DELISTED
Sealed Air
SEE
| $227M | 1.56% |
5,660,228
+326,156
| +6% | +$13.5M |
2017 Q1
6 quarters
|
|
13
Quest Diagnostics
DGX
$25.8B
| $226M | 1.55% |
2,092,866
-565,264
| -21% | -$62M |
2017 Q1
6 quarters
|
|
14
Danaher
DHR
$161B
| $176M | 1.21% |
1,830,675
+346,224
| +23% | +$31.5M |
2013 Q4
19 quarters
|
|
15
Agilent Technologies
A
$48.6B
| $174M | 1.2% |
2,471,337
-493,983
| -17% | -$32.7M |
2013 Q2
21 quarters
|
|
16
Carlisle Companies
CSL
$13.1B
| $172M | 1.18% |
1,415,107
-328,709
| -19% | -$40.1M |
2017 Q1
6 quarters
|
|
17
Equifax
EFX
$18.9B
| $169M | 1.16% |
1,291,279
+403,174
| +45% | +$52.5M |
2017 Q2
5 quarters
|
|
18
Cintas
CTAS
$84.4B
| $166M | 1.14% |
3,353,780
+728,852
| +28% | +$37.7M |
2017 Q1
6 quarters
|
|
19
Visa
V
$752B
| $159M | 1.09% |
1,060,305
+325,768
| +44% | +$46.3M |
2013 Q4
19 quarters
|
|
20
Cigna
CI
$79.4B
| $159M | 1.09% |
761,135
+344,859
| +83% | +$63.9M |
2017 Q1
6 quarters
|
|
|
21
Vertex Pharmaceuticals
VRTX
$127B
| $155M | 1.07% |
804,761
-583,039
| -42% | -$104M |
2017 Q1
6 quarters
|
|
22
DELISTED
Berry Global Group, Inc.
BERY
| $154M | 1.06% |
3,472,557
-654,629
| -16% | -$28.8M |
2013 Q4
19 quarters
|
|
23
Humana
HUM
$50.2B
| $151M | 1.04% |
445,234
+155,010
| +53% | +$50.4M |
2017 Q1
6 quarters
|
|
24
Roper Technologies
ROP
$37.7B
| $150M | 1.03% |
507,364
+124,939
| +33% | +$36.8M |
2017 Q4
3 quarters
|
|
25
US Foods
USFD
$21.9B
| $137M | 0.94% |
4,443,836
+981,494
| +28% | +$33.9M |
2017 Q4
3 quarters
|
|
Similar funds
NAM
Marshall Wace North America's Q3 2018 Portfolio in Review
As of Q3 2018, Marshall Wace North America held 1,655 positions worth $14.6B, down 18% from $17.7B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Marshall Wace North America withdrew a net $4.07B in Q3 2018, closing 770 positions and reducing 349 holdings. Its most notable exit was Baidu, an estimated $120M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 26% a quarter earlier, followed by Technology and Industrials.
Against the trend, Marshall Wace North America opened a new position in Medtronic worth $130M.
- Marshall Wace North America's largest Q3 2018 buy was Medtronic: 1,325,878 shares worth $130M.
- Marshall Wace North America added most to Alphabet (Google) Class A in Q3 2018, an estimated $214M increase.
- Marshall Wace North America's biggest Q3 2018 reduction was Meta Platforms (Facebook), cutting an estimated $253M.
- Marshall Wace North America fully exited Baidu in Q3 2018, selling an estimated $120M.
- Marshall Wace North America's ten largest holdings make up 21% of its $14.6B portfolio in Q3 2018.
- Marshall Wace North America opened 313 new positions and closed 770 in Q3 2018.
- Marshall Wace North America's portfolio value fell 18% quarter-over-quarter to $14.6B.
Based on Marshall Wace North America's 13F filing for Q3 2018, filed 14 Nov 2018.